The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gusev L.L.

City clinical hospital named after N.I. Pirogov, Moscow, Russia

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Andriiashkin V.V.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Zolotukhin I.A.

Pirogov Russian National Research Medical University, Moscow, Russia

Prevention of relapses of deep vein thrombosis in the lower extremities (a literature review)

Authors:

Gusev L.L., Leont'ev S.G., Andriiashkin V.V., Zolotukhin I.A.

More about the authors

Journal: Journal of Venous Disorders. 2011;5(4): 72‑78

Read: 5743 times

Download PDF (RU)
Contact the author
Table of contents

PREVENTION OF RELAPSES OF DEEP VEIN THROMBOSIS IN THE LOWER EXTREMITIES (A LITERATURE REVIEW)
PREVENTION OF RELAPSES OF DEEP VEIN THROMBOSIS IN THE LOWER EXTREMITIES (A LITERATURE REVIEW)

To cite this article:

Gusev LL, Leont'ev SG, Andriiashkin VV, Zolotukhin IA. Prevention of relapses of deep vein thrombosis in the lower extremities (a literature review). Journal of Venous Disorders. 2011;5(4):72‑78. (In Russ.)

Подписка 2026 Флебология (Journal of Venous Disorders)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Mechanical Endo­vascular Thro­mboextraction and Catheter-Directed Thro­mbolysis in Patients with Iliofemoral Deep Vein Thro­mbosis of the Lower Extremities: a Single-Center Prospective Cohort Study. Journal of Venous Diso­rders. 2025;(3):198-205
Signs of high embo­lic risk in iliocaval floating thro­mbi. Piro­gov Russian Journal of Surgery. 2025;(3):56-62
Modern approach to the treatment of acute iliofemoral thro­mbosis. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):293-299
A clinical case of treating a patient with severe ischemic stroke and cancer. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):114-117
Effi­cacy and Safety of the Oral Anti­coagulant DIMO­LEGIN Compared to Enoxaparin Sodium for the Prevention of Venous Thro­mboembolism Following Major Joint Replacement Surgery (hip or knee arthroplasty): A Randomized, Double-Blind, Multicenter Trial. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):577-585
Sagi­ttal sinus thro­mbosis during pregnancy with the deve­lopment of ischemic stroke. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):87-91
Thro­mbotic complications in pancreatitis: diagnostics and prevention. Russian Journal of Preventive Medi­cine. 2025;(10):115-122
Portal vein thro­mbosis: obse­rvations from the practice. Russian Bulletin of Obstetrician-Gynecologist. 2025;(6):59-63
Risk factors of deep vein thro­mbosis after arrhythmia-related catheter inte­rventions. Russian Cardiology Bulletin. 2025;(4):80-86
Abstract:

Undeservedly little attention is given in the clinical practice to the problem of prevention of venous thromboembolic complications (VTEC). Not infrequently, the physicians are reluctant to prescribe secondary prophylaxis of such complications referring, without any good reason, to the high risk of hemorrhage. Currently, a search for new groups of efficacious and safe pharmaceutical products is underway for the prevention of VTEC that are free of negative properties of vitamin K antagonists usually used for standard therapy of these complications. At present, the majority of these preparations are being studied at different phases of clinical trials and can not yet be recommended for the application in routine clinical practice. The authors present a review of the literature data concerning the use of low molecular weight heparins that do not require thorough laboratory monitoring and are known to rarely induce thrombocytopenia when employed as the tools for secondary prophylaxis of VTEC.

Keywords:

deep vein thrombosis
anticoagulation therapy

Authors:

Gusev L.L.

City clinical hospital named after N.I. Pirogov, Moscow, Russia

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Andriiashkin V.V.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Zolotukhin I.A.

Pirogov Russian National Research Medical University, Moscow, Russia

Close metadata

References:

  1. Cohen A.T. Presented at the 5th Annual Congress. Eur Fed Int Med 2005.
  2. Lindblad B., Eriksson A., Bergquist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1968. Br J Surg 1991; 78: 849-852.
  3. Sandler D.A., Martin J.F. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203-205.
  4. et al. Rossiiskii statisticheskii ezhegodnik 2004.
  5. Dahl O.E., Gudmundsen T.E., Bj_rnara B.T., Solheim D.M. Risk of Clinical PE after Joint Surgery in Patients Receiving In-Hospital Low-Molecular-Weight Heparin Prophylaxis - A 10-Year Prospective Registry of 3,954 Patients. Acta Orthopaedica Scandinavica 2003.
  6. Bick R.L. Therapy for venous thrombosis: guidelines for a competent and cost-effective approach. Clin Appl Thromb Hemost 1999; 5: 1: 2-9.
  7. Lipnitskii E.M. Lechenie troficheskikh yazv nizhnikh konechnostei. M 2001; 160.
  8. Savel'ev V.S. Lechenie troficheskikh yazv venoznoi etiologii: posobie dlya vrachei. M 2000; 3-3.
  9. Rucley S.V. Socioeconomic impact of chronic venous infficiency and leg ulcer. Angiolog 1997; 48: 67-69.
  10. Clagett G.P., Reisch J.S. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988; 208: 227-240.
  11. et al. International Multicenter Trial. Prevention of fatal pulmonary embolism by low doses of heparin. Lancet 1975; 2: 45-51.
  12. Koch A., Ziegler S., Breitschwerdt H. et al. Low molecular weigh heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 2001; 102: 295-309.
  13. et al. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii. Flebologiya 2010; 1: 2: 3-37.
  14. SulimovV.A., Belentsov S.M., Golovina N.I., Dubrovnaya N.I. ENDORSE: mezhdunarodnyi proekt po vyyavleniyu gospital'nykh bol'nykh, imeyushchikh risk venoznykh tromboembolicheskikh oslozhnenii. Rezul'taty rossiiskogo registra u bol'nykh khirurgicheskogo profilya. Flebologiya 2009; 1: 1: 15-18.
  15. Geerts W.H., Pineo G.F., Heit J.A. et al. Prevention of venous thromboembolism: the seventh ACCP conference on Antithrombotic and Thrombotic Therapy. Chest 2004; 126: 338S-400S.
  16. Savel'ev V.S., Kirienko A.I., Zolotukhin I.A., Andriyashkin A.V. Profilaktika posleoperatsionnykh venoznykh tromboembolicheskikh oslozhnenii v rossiiskikh statsionarakh (predvaritel'nye rezul'taty proekta "Territoriya bezopasnosti"). Flebologiya 2010; 1: 3: 3-20.
  17. Zolotukhin I.A., Yumin S.M., Leont'ev S.G., Andriyashkin V.V., Kirienko A.I. Ambulatornoe lechenie patsientov, perenesshikh tromboz glubokikh ven: kak vypolnyayutsya vrachebnye rekomendatsii. Flebologiya 2010; 2: 4: 24-28.
  18. Zolotukhin I.A., Yumin S.M., Leont'ev S.G., Andriyashkin V.V., Kirienko A.I. Otdalennye rezul'taty lecheniya patsientov, perenesshikh tromboz glubokikh ven nizhnikh konechnostei. Flebologiya 2011; 1: 5: 25-31.
  19. Savi P., Chong B.H., Greinhacher A. et al. Prevention of venous thromboembolism. Chest 2001; 119: Suppl 1: 1329-1759.
  20. Hamer J., Ramelet A., Schmeller W., Brunner U. Management of Leg Ulcers. KARGER 1999; 294.
  21. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: Suppl I: 22.
  22. Kearon C. Long-term management of patients after venous thromboemboliism. Circulation 2004; 110: Suppl I: 10-18.
  23. Samama Ch.M., Samama M.M. Prevention of venous thromboembolism. Congress of European Society of Anaesthesiology. Amsterdam 1999; 39-43.
  24. Widmer L.K., Zemp E., Widmer M.T. et al. Late results in deep vein thrombosis of the lower extremity. Vasa 1985; 14: 264-268.
  25. et al. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992; 340: 873-876 [PMID: 0001357297].
  26. Anand S.S. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Vasc Med 2001; 6: 4: 269-270.
  27. Kirienko A.I., Matyushenko A.A., Andriyashkin V.V. Ostryi venoznyi tromboz: bazovye printsipy terapii. Consilium Medicum 2001; 3: 7: 1-7 (prilozhenie).
  28. Hyers T.M., Agnelly G., Hull R.D. et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114: 561-578.
  29. Pinede L., Cucherat M., Duhaut P. et al. Optimal duration of anticoagulant therapy after an episode of venous thromboembolism. Blood Coagul Fibrinolysis 2000; 11: 8: 701-707.
  30. Prandoni P. Long-term clinical course of proximal deep venous thrombosis and detection of recurrent thrombosis. Semin Thromb Hemost 2001; 27: 1: 9-13.
  31. Schafer A.I. Warfarin for venous thromboembolism - walking the dosing tightrope. N Engl J Med 2003; 348: 15.
  32. Geerts W.H., Heit J.A., Clagett G.P. et al. Prevention of venous thromboembolism. Chest 2001; 119: Suppl 1: 132-175.
  33. Kearon C., Gent M., Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
  34. Eichinger S., Stumpflen A., Hirschl M. et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 556-569.
  35. Crippa L., Barone M. et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002; 87: 515-522.
  36. Schulman S., Granqvist S., Holmstrom M. et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: the Duration of Anticoagulation Trial Study Group. N Engl Med 1997; 336: 393-398.
  37. Prandoni P., Lensing A.W., Prins M.H. et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 12: 955-960.
  38. Geerts W.H., Bergqvist D., Pineo G.F. et al. Prevention of Venous Thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
  39. Amiral J. Molecular markers in thrombosis and hemostasis. Clin Appl Thromb Hemost 1997; 3: 71-81.
  40. Elias A., Bonfils S., Daoud-Elias M. et al. Influence of long term oral anticoagulants upon prothrombin fragment 1+2, thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb Haemost 1993; 69: 302-305.
  41. Bates S.M., Grand'MaisonA., Johnston M. et al. A latex D-dimer reliably excludes venous thromboembolism. Arch Intern Med 2001; 161: 447-453.
  42. Owen Ch.A., Nichols W.L., Walter Bowie E.J. A History of Blood Coagulation. Mayo Found Med Educ Res 2001; 257-259.
  43. Bouchet A. Histoire de la therapeutique anti-coagulante. Cahiers Med Lyonnais 1969; 45: 4: 637.
  44. Clagett G.P., Anderson F.A.Jr., Geerts W., Heit J.A., Knudson M., Lieberman J.R. et al. Prevention of venous thromboembolism. Chest 1998; 114: 531S-560S. [PMID: 0009822062].
  45. Holm H.A., Ly B., Handeland G.F., Abildgaard U., Arnesen K.E., Gottschalk P. et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16: Suppl 2: 30-37. [PMID: 0003527886].
  46. Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and lowmolecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
  47. Edes T.E. Heparin-induced hyperkalemia. Eds. T.E. Edes, E.V. Sunderrajan. Arch Int Med 1985; 145: 1070-1072.
  48. Goldhaber S.Z., Meyerovitz M.F., Green D. et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990; 88: 235-240.
  49. Schwartz K.A., Royer G., Kaufman D.B. et al. Complications of heparin administration in normal individuals. Am J Hematol 1985; 19: 355-363.
  50. Gould M.K., Dembitzer A.D., Sanders G.D. et al. Low molecular weight heparins compared with unfractionated heparin for the treatment of acute deep vein thrombosis. A cost-effectiveness analysis. Ann Int Med 1999; 130: 789-799.
  51. Boshcov L.K., Warkentin T.E., Hayward C.P. et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Heamatol 1993; 84: 322-328.
  52. Kelton J.G. Heparin-induced thrombocytopenia. Haemostasis 1986; 16: 173-186.
  53. Magnani H.N. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran. Thromb Haemost 1993; 70: 554-561.
  54. Barkagan Z.S., Buevich E.I., Timoshenko E.A. Trombofiliya, kharakterizuyushchayasya rezistentnost'yu k antikoagulyantam pryamogo deistviya. Ter arkh 1995; 7: 50-52.
  55. Bokarev I.N. Sovremennye dostizheniya i problemy protivotromboticheskoi terapii. Ter arkh 1993; 65: 10: 101-105.
  56. Cines D.B., Tomaski A., Tannenbaum S. Immune endothelial-cell injury in the heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 581-589.
  57. Greinacher A., Michel I., Kiefel V. et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-736.
  58. Warkentin T.E., Chong B.H., Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Tromb Haemost 1998; 79: 1-7.
  59. Warkentin T.E., Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia. New York: Marcel Dekker Inc 2000; 211-244.
  60. Barkagan Z.S., Momot A.P., Taranenko I.A. i dr. Osnovy prolongirovannoi profilaktiki i terapii tromboembolii antikoagulyantami nepryamogo deistviya (pokazaniya, podbor doz, laboratornyi monitoring). Metodicheskie ukazaniya. Barnaul 2002; 53.
  61. Makatsariya A.D., Bitsadze V.O. Trombofilicheskie sostoyaniya v akusherskoi praktike. M: Russo 2001; 704.
  62. Panchenko E.P., Dobrovol'skii A.B. Trombozy v kardiologii. Mekhanizmy razvitiya i vozmozhnosti terapii. M: Sport i kul'tura 1999; 464.
  63. Palmer A.J., Koppenhagen K., Kirchhov B. et al. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. Haemostasis 1997; 27: 75-84.
  64. Vigano S., Mannuci P.M., Solanis S. et al. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984; 57: 213-220.
  65. Cavel'ev V.S., Gologorskii V.A., Kirienko A.I. i dr. Flebologiya. Rukovodstvo dlya vrachei. M: Meditsina 2001; 664.
  66. Khamashta M.A., Cuadrado M.J., Mujic R. et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
  67. Hirsh J., Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Circulation 1994; 89: 1469-1480.
  68. Wells P.S., Holbrook A.M., Crowther R. et al. Warfarin and its drug/food interactions; a critical appraisal of the literature. Ann Int Med 1994; 121: 676-683.
  69. Schulman S., Rhedin A.S., Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665.
  70. Tait R.C., Sefcick A. A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation. Br J Naematol 1998; 101: 450-454.
  71. Vadher B.D., Patterson D.L.H., Leaning M.S. Validation of an algorithm for oral anticoagulant dosing and appointment scheduling. Clin Lab Haematol 1995; 17: 339-345.
  72. Doyle J.J., Koren G., Cheng M.Y., Blanchette V.S. Anticoagulation with sodium warfarin in children: effect of a loading regimen. J Pediat 1988; 113: 1095-1097.
  73. James A.H., Britt R.P., Raskino C.L., Thompson S.G. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45: 704-706.
  74. Bentley D.P., Backhouse G., Hutchings A. et al. Investigation of patients with abnormal response to warfarin. Br J Clin Pharmacol 1986; 22: 37-41.
  75. Diab F., Feffer S. Hereditary warfarin resistance. South Med J 1994; 87: 407-409.
  76. O'Reilly R. Vitamin K in hereditary resistance to oral anticoagulant drugs. Am J Physiol 1971; 221: 1327-1330.
  77. Furuya H., Fernandez-Salguero P., Gregory W. et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5: 389-392.
  78. Crowther M.A., Harrison L., Hirsh J. Warfarin (Less may be better-in response). Ann Int Med 1997; 127: 333.
  79. Harrison L., Johnston M., Massicotte M.P. et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Int Med 1997; 126: 133-136.
  80. Crowther M.A., Ginsberg J.B., Kearon C. et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Int Med 1999; 159: 46-48.
  81. Fennerty A., Dolben J., Thomas P. et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ (Clin Res Ed) 1984; 288: 1268-1270.
  82. Gedge J., Orme S., Hampton K.K. et al. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 2000; 29: 31-34 [see comments].
  83. Poller L., Wright D., Rowlands M. Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol 1993; 46: 299-303.
  84. Vadher B., Patterson D.L., Leaning M. Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. BMJ 1997; 314: 1252-1256.
  85. White R.H., Hong R., Venook A.P. et al. Initiation of warfarin therapy (comparison of physician dosing with computer-assisted dosing). J Gen Int Med 1987; 2: 141-148.
  86. Sun J., Chang M.W. Initialization of warfarin dosages using computer modeling. Arch Phys Med Rehabil 1995; 76: 453-456.
  87. Phillips W.S., Smith J., Greaves M. et al. An evaluation and improvement program for inpatient anticoagulant control. Thromb Haemost 1997; 77: 283-288.
  88. Ellis R.F., Stephens M.A., Sharp G.B. Evaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy. Am J Hosp Pharm 1992; 49: 387-394.
  89. Landefeld C.S., Anderson P.A. Guideline-based consultation to prevent anticoagulant-related bleeding. A randomized, controlled trial in a teaching hospital. Ann Int Med 1992; 116: 829-837.
  90. Rospond R.M., Quandt C.M., Clark G.M., Bussey H.I. Evaluation of factors associated with stability of anticoagulation therapy. Pharmacotherapy 1989; 9: 207-213.
  91. Duxbury B.M. Therapeutic quality control leading to further clinical assessment of oral anticoagulation. Acta Haematol 1986; 76: 65-67.
  92. Huber K.C., Gersh B.J., Bailey K.R. et al. Variability in anticoagulation control predicts thromboembolism after mechanical cardiac valve replacement (a 23-year population-based study). Mayo Clin Proc 1997; 72: 1103-1110.
  93. McCurdy S.A., White R.H. Accuracy and precision of a portable anticoagulation monitor in a clinical setting. Arch Int Med 1992; 152: 589-592.
  94. Triplett D.A. Current recommendations for warfarin therapy. Use and monitoring. Med Clin North Am 1998; 82: 601-611.
  95. Tiede D.J., Nishimura R.A., Gastineau D.A. et al. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc 1998; 73: 665-680.
  96. Ryan P.J., Gilbert M., Rose P.E. Computer control of anticoagulant dose for therapeutic management. BMJ 1989; 299: 1207-1209.
  97. White R.H., Zhou H., Romano P., Mungall D. Changes in plasma warfarin levels and variations in steady-state prothrombin times. Clin Pharmacol Ther 1995; 58: 588-593.
  98. Britt R.P., James A.H., Raskino C.L., Thompson S.G. Factors affecting the precision of warfarin treatment. J Clin Pathol 1992; 45: 1003-1006.
  99. Fredriks D.A., Coleman R.W. Nomogram for dosing warfarin at steady state. Clin Pharm 1991; 10: 923-927.
  100. Ansell J.E., Patel N., Ostrovsky D. et al. Long-term patient self-management of oral anticoagulation. Arch Int Med 1995; 155: 2185-2189.
  101. Ansell J.E., Buttaro M.L., Thomas O.V., Knowlton C.H. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. Ann Pharmacother 1997; 31: 604-615.
  102. White R.H., Mungall D. Outpatient management of warfarin therapy (comparison of computer-predicted dosage adjustment to skilled professional care). Ther Drug Monit 1991; 13: 46-50.
  103. Wilson R., James A.H. Computer assisted management of warfarin treatment. BMJ (Clin Res Ed) 1984; 289: 422-424.
  104. Kubie A., James A.H., Timms J., Britt R.P. Experience with a computer-assisted anticoagulant clinic. Clin Lab Haematol 1989; 11: 385-391.
  105. Johnston M.E., Langton K.B., Haynes R.B., Mathieu A. Effects of computer-based clinical decision support systems on clinician performance and patient outcome. A critical appraisal of research. Ann Int Med 1994; 120: 135-142.
  106. Fitzmaurice D.A., Hobbs F.D., Murray E.T. et al. Evaluation of computerized decision support for oral anticoagulation management based in primary care. Br J Gen Pract 1996; 46: 533-535.
  107. Margolis A., Flores F., Kierszenbaum M. et al. Warfarin 2.0-a computer program for warfarin management. Design and clinical use. Proc Ann Sympos Comput Appl Med Care 1994; 17: 846-850.
  108. Lee C., Coleman R.W., Mungall D.R. Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response. Clin Pharm 1987; 6: 406-412.
  109. Poller L., Shiach C.R., MacCallum P.K. et al. Multicentre randomised study of computerised anticoagulant dosage. Lancet 1998; 352: 1505-1509.
  110. Ageno W., Turpie A.G. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. Thromb Res 1998; 91: 237-240.
  111. Kumar S., Haigh J.R., Rhodes L.E. et al. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb Haemost 1989; 62: 729-732.
  112. Sorano G.G., Biondi G., Conti M. et al. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients (a clinical practice proposal). Haemostasis 1993; 23: 77-82.
  113. Fihn S.D., McDonell M., Martin D. et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Int Med 1993; 118: 511-520.
  114. Fairweather R.B., Ansell J., van den Besselaar A.M. et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy (laboratory monitoring of oral anticoagulant therapy). Arch Pathol Lab Med 1998; 122: 768-781.
  115. Graff J., von Hentig N., Misselwitz F. et al. Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47: 1398-1407.
  116. Eriksson B.I., Borris L., Dahl O.E. et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121-128.
  117. Eriksson B.I., Borris L.C., Dahl O.E. et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374-2381.
  118. Turpie A.G. Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007; 27: 1238-1247.
  119. Lassen M.R., Ageno W., Borris L.C. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 26: 2776-2786.
  120. Gustafsson D., Nystrom J., Carlsson S. et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-181.
  121. Caprini J.A., Hwang E., Hantel S. et al. The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopaedic surgery. J Thromb Haemost 2007; 5: Abstract O-W-050.
  122. Stangier J., Eriksson B.I., Dahl O.E. et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-563.
  123. Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med 2009; 361: 2342-2352.
  124. Hirsh J., Guyatt G., Albers G.W. et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines. Chest 2004; 126: 172S-173S.
  125. Moiseev V.S. Nizkomolekulyarnye gepariny. Klin farmakol i ter 2000; 9: 1: 2-8.
  126. Simonneau G., Sors H., Charbonnier B. et al. A comparison LMWH with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669.
  127. Dolovich L.R., Ginsberg J.S., Douketis J.D. et al. A metaanalysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type and dosing frequency. Arch Int Med 2000; 160: 181-188.
  128. Breddin H.K., Hach-Wunderle V., Nakov R. et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344: 626-631.
  129. Hull R.D., Raskob G.E., Brant R.F. et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Int Med 2000; 160: 229-236.
  130. Levine M., Gent M., Hirsh J. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681.
  131. Spyropoulos A.C., Hurley J.S., Ciesla G.N. et al. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002; 122: 1: 108-114.
  132. Boucher M., Rodger M., Johnson J.A. et al. Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care center: a cost-minimization analysis. Pharmacotherapy 2003; 23: 3: 301-309.
  133. Wells P.S. Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism. Curr Opin Pulm Med 2001; 7: 5: 360-364.
  134. Merli G., Spiro T.E., Olsson C.G et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Int Med 2001; 134: 191-202.
  135. Barkagan Z.S., Tsyvkina L.P., Momot A.P. i dr. Oshibki, proschety i puti sovershenstvovaniya klinicheskogo primeneniya nizkomolekulyarnykh geparinov. Klin farm i ter 2002; 11: 1: 78-83.
  136. Ginsberg J.S., Bates S.M. Management of venous thromboembolism during pregnancy. J Thromb Haemost 2003; 1: 1435-1442.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.